TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01734187

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (30g/day)
Study: NCT04194658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
Study: NCT01313533

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vein soak treated with Lactated Ringers Solution
Description: Vein soak
Study: NCT03531580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
Study: NCT00917501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMega 3
Description: Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given twice a day which will be compared to Omega 3
Study: NCT01146821

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 0.20 gm/kg fish oil
Description: Group 2: 7 patients will receive 0.20gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 0.50 gm/kg fish oil
Description: Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care.
Study: NCT03598348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib+Capecitabine
Description: Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg po Qd
Study: NCT00725855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: 1 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: 5 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: 15 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: 50 mg dose
Study: NCT01972152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lilly Glucagon(TM) 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen(TM) 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen(TM) 0.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-Pen(TM) 0.5 mg
Study: NCT04159636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Description: The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
Study: NCT00725855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEM 3454
Description: Placebo dose
Study: NCT04150445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet treatment for overweight and obese patients
Description: The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
Study: NCT02444247

Intervention type: OTHER
Group type: OTHER
Intervention: High Dose Exercise (300 kcal)
Description: Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Low Dose Exercise (150 kcal)
Description: Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: No Exercise (0 kcal)
Description: Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Sedentary Option
Description: Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Sedentary Option
Description: Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Sedentary Option
Description: Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
Study: NCT03722069

Intervention type: OTHER
Group type: OTHER
Intervention: Low sodium diet
Description: Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal sodium diet
Description: Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
Study: NCT04198116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline 2mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 2mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine ER
Description: Guanfacine Extended Release (6mg/day ER)
Study: NCT03624985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Lidocaine Infusion
Description: Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
Study: NCT01870050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone gel - verum
Study: NCT01393301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy for smoking cessation and anxiety
Description: Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
Study: NCT01967407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE)
Description: Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
Study: NCT03403699

Intervention type: BIOLOGICAL
Intervention: Generation of inducible pluripotent stem cells
Description: Generation of inducible pluripotent stem cells from peripheral blood cells.

Intervention type: BIOLOGICAL
Intervention: Generation of inducible pluripotent stem cells
Description: Generation of inducible pluripotent stem cells from peripheral blood cells.
Study: NCT00931593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)
Description: Visit V0 (day 0 - 2 to 14 days):~* Subject selection~* Obtaining of written informed consent~Visit V1 (day 0):~* Fasting subject~* Randomization to determine the examination order~* Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~* Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study
Study: NCT03829267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eFIT Intervention
Description: eFIT: social network accountability partners, a psychosocial intervention to increase physical activity in persons with multiple sclerosis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eJournal Intervention
Description: 1-hour online each week engaged in an active journaling activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Participants in this condition will complete baseline and follow-up surveys with the same frequency as the active treatment groups, but will receive neither eFIT nor eJournal.
Study: NCT01393301

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Enhanced standard smoking cessation treatment and NRT.
Study: NCT00833820

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS of the brain
Description: Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS of the brain
Description: Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
Study: NCT03829267

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants in this condition will complete baseline and follow-up surveys with the same frequency as the active treatment groups, but will receive neither eFIT nor eJournal.
Study: NCT01446926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine High Dose (Formulation 1)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tris buffered saline (Placebo)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine High Dose (Formulation 1)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tris buffered saline (Placebo)
Description: 0.5 mL, Intramuscular
Study: NCT03555903

Intervention type: OTHER
Intervention: Endometriosis cohort
Description: The investigator record data on risks factors, symptoms (pain), quality of life (using standardized quality of life questionnaires), infertility history, and management of the disease with a 5-years follow up.~Different surgical procedures exist to treat DIE and are they are described in the database, to allow comparison.
Study: NCT02338076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrolatum application under occlusion
Description: Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)
Study: NCT00912158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy (ST)
Description: standard medical therapy
Study: NCT02050958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXP001
Study: NCT03524066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation
Description: Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic
Description: Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
Study: NCT02050958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT03524066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
Study: NCT02871440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optive Advanced

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Study: NCT03321942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group
Description: Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Conventional treatment were used to treat patients with chronic renal failure.
Study: NCT03202303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidivarin
Description: Weight-based dosing of 10 mg/kg/day of CBDV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Weight-based dosing of 10 mg/kg/day of placebo
Study: NCT00706173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 10-20 mg PO daily for 4 weeks.
Study: NCT01446926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Low Dose (Formulation 2)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tris buffered saline (Placebo)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Middle Dose (Formulation 3)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Middle Dose (Formulation 4)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tris buffered saline (Placebo)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine High Dose (Formulation 1)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tris buffered saline (Placebo)
Description: 0.5 mL, Intramuscular
Study: NCT02722369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Maintenance Agent
Study: NCT02351375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
Study: NCT00371566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib oral tablets
Study: NCT02351375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntelliCap® system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntelliCap® system
Study: NCT03226860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Myoelectric Stimulator
Description: Electrical stimulation during gait for children with CP
Study: NCT00371566

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03226860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5210
Description: Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
Study: NCT01388595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLUTICASONE PROPRIONATE
Description: 1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported \& QP release tested in UK : DHP Clinical supplies, Powys, UK
Study: NCT00794703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin (Mycamine)
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: oral
Study: NCT01757327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erismodegib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00722423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated care model
Description: The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Model
Study: NCT02275858

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stiffening wire
Description: Stiffening wire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stiffening wire
Description: Stiffening wire

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wire
Description: Placebo wire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo wire
Description: Placebo wire
Study: NCT00131508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 0.6 gm/kg of oral glutamine per day, in two doses for one year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01804023

Intervention type: OTHER
Intervention: HEC placebo gel applicators
Description: Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators.
Study: NCT04948528

Intervention type: OTHER
Intervention: Active Comparator: Surgery Pathology or Cystoscopy
Description: Case group will be followed up with surgery pathology or cystoscopy.

Intervention type: OTHER
Intervention: Active Comparator: Clinical Diagnosis
Description: Control group will be diagnosed in clinical.
Study: NCT02103907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted dynamic balance training
Description: Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
Study: NCT03270371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medium cut off dialysis
Description: Hemodialysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard High Flux Dialyzer
Description: Hemodialysis
Study: NCT01950169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement
Description: The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D3
Description: The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D3
Description: The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D3
Description: The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.